Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib

Annals of Oncology

Volumn 19, Issue 11, 2008, Pages 1975-

  Loriot, Y ^a   Boudou rouquette, P ^a   Billemont, B ^a   Ropert, S ^a   Goldwasser, F ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; MESALAZINE; SORAFENIB; SUNITINIB;

ABDOMINAL PAIN; ADRENAL METASTASIS; ADULT; BLOODY DIARRHEA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG RECHALLENGE; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HEMATOCHEZIA; HEMORRHAGIC PROCTOCOLITIS; HUMAN; KIDNEY CARCINOMA; LETTER; LUNG METASTASIS; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOPENIA; MALE; NEPHRECTOMY; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; PROCTOCOLITIS; RECTUM BIOPSY; SIGMOIDOSCOPY; THROMBOCYTOPENIA; ULCERATIVE COLITIS; WEAKNESS;

EID: 54949104422     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn566     Document Type: Letter

References (4)

1. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
2. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
3. Binion DG, West GA, Volk EE et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet 1998; 352: 1742-1746.
4. Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: Lessons for complex diseases? Lancet 2006; 367: 1271-1284.